Metabolic tumor volume predicts overall survival in patients with primary pulmonary lymphoepithelioma-like carcinoma.
Pretreatment tumor metabolic burden, measured using fluorine-18 fluorodeoxyglucose positron emission tomography/computerized tomography (18F-FDG PET/CT), has been demonstrated to predict outcomes in various types of malignancies. Additionally, Epstein-Barr virus (EBV) serum titer is associated with stages of pulmonary lymphoepithelioma-like carcinoma (LELC). The present study aimed to investigate the prognostic value of the functional parameters of 18F-FDG PET/CT in pulmonary LELC and their association with serum EBV DNA. The present retrospective study analyzed data from 71 patients with pulmonary LELC; among these, 32 patients with pulmonary LELC underwent pretreatment 18F-FDG PET/CT staging between January 2008 and December 2016. EBV viral load and functional parameters of 18F-FDG PET/CT were used for survival analysis. Multivariate analysis identified tumor stage IV as a significant predictor of poor progression-free survival [hazard ratio (HR), 4.85; P=0.049], whereas elevated total metabolic tumor volume (MTV ≥72.6 ml) independently predicted worse overall survival (OS; HR, 12.59; P=0.024). Pretreatment serum EBV DNA titer was significantly positively associated with total MTV (P=0.0337) and total lesion glycolysis (TLG; P=0.0093), but could not predict outcomes. Total MTV was an independent predictor of OS, and may guide clinical management for pulmonary LELC.
['Lin|Chun-Yu|CY|', 'Chang|Yu-Chuan|YC|', 'Wang|I-Ting|IT|', 'Hsieh|Meng-Heng|MH|', 'Wang|Chih-Wei|CW|', 'Lin|Shu-Min|SM|', 'Wu|Ching-Yang|CY|', 'Fang|Yueh-Fu|YF|']
metabolic tumor volume pulmonary lymphoepithelioma-like carcinoma fluorodeoxyglucose positron emission tomography/computerized tomography Epstein-Barr virus DNA prognosis